PMID- 26880678
OWN - NLM
STAT- MEDLINE
DCOM- 20160718
LR  - 20220318
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
VI  - 183
IP  - 6
DP  - 2016 Mar 15
TI  - Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in 
      Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam 
      Study.
PG  - 553-60
LID - 10.1093/aje/kwv188 [doi]
AB  - Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) might 
      raise the risk of type 2 diabetes mellitus (T2DM) via binding of insulin-like 
      growth factor 1 (IGF-1), an insulin-like hormone that is involved in glucose 
      homeostasis. We investigated serum concentrations of IGF-1 and IGFBP-3 and their 
      molar ratio in relation to T2DM incidence in a nested case-cohort study within 
      the European Prospective Investigation Into Cancer and Nutrition-Potsdam Study. 
      We included a randomly selected subcohort of persons without T2DM at the time of 
      blood sampling (n = 2,269) and 776 individuals with incident T2DM identified 
      between 1994 and 2005. For the highest quartile versus lowest, the 
      multivariable-adjusted hazard rate ratios were 0.91 (95% confidence interval 
      (CI): 0.68, 1.23; P for trend = 0.31) for IGF-1, 1.33 (95% CI: 1.00, 1.76; P for 
      trend = 0.04) for IGFBP-3, and 0.77 (95% CI: 0.57, 1.03; P for trend = 0.03) for 
      IGF-1:IGFBP-3 ratio. IGFBP-3 level remained positively associated with T2DM 
      incidence-and the ratio of IGF-1 to IGFBP-3 was inversely related with T2DM 
      incidence--in models that included adjustment for IGF-1 concentrations (P for 
      trend < 0.05). Therefore, our findings do not confirm an association between 
      total IGF-1 concentrations and risk of T2DM in the general study population, 
      although higher IGFBP-3 levels might raise T2DM risk independent of IGF-1 levels.
CI  - (c) The Author 2016. Published by Oxford University Press on behalf of the Johns 
      Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Drogan, Dagmar
AU  - Drogan D
FAU - Schulze, Matthias B
AU  - Schulze MB
FAU - Boeing, Heiner
AU  - Boeing H
FAU - Pischon, Tobias
AU  - Pischon T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160214
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/*epidemiology
MH  - Europe/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - insulin-like growth factor 1
OT  - insulin-like growth factor-binding protein 3
OT  - prospective study
OT  - type 2 diabetes mellitus
EDAT- 2016/02/18 06:00
MHDA- 2016/07/19 06:00
CRDT- 2016/02/17 06:00
PHST- 2015/01/12 00:00 [received]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/07/19 06:00 [medline]
AID - kwv188 [pii]
AID - 10.1093/aje/kwv188 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2016 Mar 15;183(6):553-60. doi: 10.1093/aje/kwv188. Epub 2016 Feb 
      14.